| Biotechnology Industry | Healthcare Sector | - CEO | XSTU Exchange | - ISIN |
| Sweden Country | 24 Employees | - Last Dividend | - Last Split | - IPO Date |
Xspray Pharma AB (publ) is a pharmaceutical company based in Sweden, focusing on the development of protein kinase inhibitors for targeted cancer treatments. The company was initially founded in 2003 as Xspray Microparticles AB but underwent a name change to Xspray Pharma AB (publ) in 2017 to better reflect its pharmaceutical focus. Its headquarters are located in Solna, Sweden. Xspray Pharma aims to improve cancer patient outcomes by delivering innovative treatments that target specific types of cancer more effectively.
A product candidate geared towards the treatment of chronic myeloid leukemia. XS003 is part of Xspray Pharma's commitment to developing next-generation therapies for leukemia patients.
This treatment focuses on addressing renal cancer, liver cancer, and several forms of thyroid cancer. It represents Xspray Pharma's approach to diversify its portfolio by targeting different types of cancer with potentially groundbreaking protein kinase inhibitors.
Another key product candidate from Xspray Pharma, XS004 is designed for the treatment of both chronic myeloid leukemia and acute lymphoblastic leukemia. Like XS003, it exemplifies the company's efforts to provide innovative solutions for leukemia treatment.